Closely-held Breath Therapeutics appointed Peter Shadday as chief commercial officer to lead the company’s market access activities and product commercialization.
Leerink downgraded Immune Design (NASDAQ:IMDZ) to “market perform” from “outperform” and cut its price target to $3 from $7 after the company deprioritizedlead program, CMB305, a therapeutic cancer vaccine targeting NY...
CHF Solutions (NASDAQ:CHFS) and NI Medical are collaborating to explore potential clinical synergies between CHF’s Aquadex FlexFlow System and NI Medical’s NICaS Hemodynamic Navigator to assess patient’s fluid volume...
Closely-held CellAegis Devices completed enrollment in an investigator sponsored study (FIRST) to evaluate the clinical and economic benefits of remote ischemic conditioning (RIC) therapy in the treatment of patients...
By Len Zehr Actinium Pharmaceuticals (NYSE American:ATNM) intends to improve bone marrow transplants (BMT) access and patient outcomes and treat cancers with high unmet medical needs by combining the precision of...
Ortho Regenerative Technologies (CSE:ORTH) entered into an agreement with a leading contract manufacturing organization operating within the global biopharmaceutical industry to begin work on providing Ortho RTi with...
Leerink resumed coverage of ObsEva SA (NASDAQ:OBSV) with an “outperform” rating and $25 price target. The stock finished at $13 on August 14. “We believe that at current levels the stock does not fully reflect the...
By Melane Sampson A new drug discovery paradigm, PLEOTHERAPY, developed by Pharnext SA (FR0011191287-ALPHA) is based on big genomic data, artificial intelligence, and rigorous experimental analysis that involves...
Ladenburg Thalmann lowered its price target for Scynexis (NASDAQ:SCNX) to $6 from $10, citing another delay in development of an IV formulation of ibrexafungerp. The stock closed at $1.39 on August 10. “As successful as...